Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04164199 | Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | PHASE3 | COMPLETED | 404 | — | — | Dec 19, 2019 | May 23, 2026 | Jun 3, 2026 | 106 | United States, Australia +11 |
Safety as assessed by the number of participants with immune-mediated adverse events (imAEs), ≥ Grade 3 adverse events, and serious adverse events.
| Arm | Type | Description |
|---|---|---|
| A - Tislelizumab Monotherapy | EXPERIMENTAL | - |
| B - Pamiparib Monotherapy | EXPERIMENTAL | - |
| C - Sitravatinib Monotherapy | EXPERIMENTAL | - |
| D - BGB-15025 Monotherapy | EXPERIMENTAL | - |
| E - Zanidatamab Monotherapy | EXPERIMENTAL | - |
| F - Pamiparib and Temozolomide Combination Therapy | EXPERIMENTAL | - |
| G - Tislelizumab and Pamiparib Combination Therapy | EXPERIMENTAL | - |
| H - Tislelizumab and Sitravatinib Combination Therapy | EXPERIMENTAL | - |
| I - Tislelizumab and Ociperlimab Combination Therapy | EXPERIMENTAL | - |
| J - Tislelizumab and BAT1706 Combination Therapy, or BAT1706 Monotherapy | EXPERIMENTAL | - |
| K - Tislelizumab and Fruquintinib Combination Therapy | EXPERIMENTAL | - |
| L - Tislelizumab and BGB-A445 Combination Therapy | EXPERIMENTAL | - |
| M - Tislelizumab and Surzebiclimab Combination Therapy | EXPERIMENTAL | - |
| N - Tislelizumab and BGB-15025 Combination Therapy | EXPERIMENTAL | - |
| O - Tislelizumab and Lenvatinib Combination Therapy | EXPERIMENTAL | - |
| P - Tislelizumab and Zanidatamab Combination Therapy | EXPERIMENTAL | - |
| Q - Tislelizumab and LBL-007 Combination Therapy | EXPERIMENTAL | - |
| R - Tislelizumab and Surzebiclimab and LBL-007 Combination Therapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Tislelizumab | DRUG | Administered intravenously. |
| Pamiparib | DRUG | Administered orally. |
| Temozolomide | DRUG | Administered orally. |
| Sitravatinib | DRUG | Administered orally. |
| Ociperlimab | DRUG | Administered intravenously. |
| BAT1706 | DRUG | Administered intravenously. |
| Fruquintinib | DRUG | Administered orally. |
| BGB-15025 | DRUG | Administered orally. |
| Zanidatamab | DRUG | Administered intravenously. |
| BGB-A445 | DRUG | Administered intravenously. |
| Surzebiclimab | DRUG | Administered intravenously. |
| Lenvatinib | DRUG | Administered orally. |
| LBL-007 | DRUG | Administered intravenously. |
Key Inclusion Criteria: 1. Currently participating in a BeiGene- or BeOne-sponsored eligible parent study 2. Fulfills treatment criteria specified in the parent study protocol 3. In the opinion of the investigator, the participant will continue to benefit from and tolerate any of the parent study t...